Neuroscience

#Alzheimer's #Drug discovery #Neurodegenerative disorders #Neurology

Study opens up new therapeutic pathways in Alzheimer’s disease 

A research team from VIB-KU Leuven and the UK Dementia Research Institute has discovered how neurons die in Alzheimer’s disease, opening new pathways for potential future treatments.  A new research paper published in Science illustrates how neurons initiate a programmed form of cell death, known… Read More

#News

Long Covid
#Covid-19 #Immunology #Long Covid #Psychiatry #SARS-CoV-2

New post-Covid study links infection and retrovirus 

A Translational Psychiatry publication indicates that SARS-CoV-2 infection, even when unnoticed or asymptomatic, can have an influence on the activation of the Human Endogenous Retrovirus W (W-ENV) protein in psychotic patients, in a context of innate immune inflammation.   GeNeuro, a biopharmaceutical company developing treatments… Read More

#Covid-19 #News

Stephen Back and Philip Adeniyi, OHSU School of Medicine
#Alzheimer's #Dementia #Neurodegenerative disorders #Neuroscience #Oregon Health & Science University

Scientists discover new target for Alzheimer’s drugs

Researchers have discovered a new avenue of cell death in Alzheimer’s disease and vascular dementia. A new study, led by scientists at Oregon Health & Science University (OHSU), has revealed that a form of cell death known as ferroptosis – caused by a build-up of iron… Read More

#Editor's Choice #News

#Artificial intelligence (AI) #Breast cancer #Head and neck cancer #Immunotherapy #Long Covid #Monoclonal antibodies #Oncology #Parkinson's #Stem cells

New DDW Highlights podcast out now

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  This week’s headline news features a stem-cell derived Parkinson’s therapy, a monoclonal antibody for… Read More

#News

Canary Wharf, London
#AviadoBio #Biotech hubs #Laboratory #London #London Innovation Centre #Neuroscience

Life sciences hub at Canary Wharf sees rapid growth

Kadans’ London Innovation Centre at Canary Wharf, London has launched its wet lab innovation and flexible workspace centre and welcomed a new tenant. AviadoBio, a gene therapy company developing medicines for neurodegenerative disorders, will establish laboratory and office presence at the Innovation Centre. The… Read More

#News

#Artificial intelligence (AI) #Breast cancer #Head and neck cancer #Immunotherapy #Long Covid #Monoclonal antibodies #Oncology #Parkinson's #Stem cells

This week in drug discovery (28 August – 1 September)  

News round-up for 28 August – 1 September by DDW Digital Content Editor Diana Spencer. This week’s headline news features a stem-cell derived Parkinson’s therapy, a monoclonal antibody for head and neck cancer, an estrogen receptor degrader for breast cancer, a mitochondrial activator for long Covid,… Read More

#News

#Alzheimer's #Dementia #Neurodegenerative disorders #Neuroinflammation #Neuroscience

New DDW Highlights podcast out now

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The headline news this week reflects the high level of interest and investment in… Read More

#News

Degeneration of dopaminergic neuron in Parkinson's disease
#Bayer #BlueRock Therapeutics #Neurodegenerative disorders #Neuroscience #Parkinson's #Stem cells

Stem cell derived Parkinson’s therapy shows promise

A stem cell derived investigational therapy for treating Parkinson’s disease has shown promise in early clinical trials. BlueRock Therapeutics, a subsidiary of Bayer, has announced details of the positive data from a Phase I clinical trial for bemdaneprocel (BRT-DA01). The data were presented at… Read More

#News #Trending News

Autophagy
#ALS #Autophagy #Healthspan #Neurodegenerative disorders #Parkinson's #Turning Science into Business

Turning Science into Business: Inducing autophagy to treat disease

DDW’s Diana Spencer speaks to Peter Hamley, Chief Scientific Officer of Samsara Therapeutics, to understand the role autophagy plays in neurodegenerative diseases and how boosting this process could increase healthspan. DS: Samsara’s autophagy inducing candidate SAM001 will be the first agent of its class to enter clinical trials. What is… Read More

#Exclusive Content

#Alzheimer's #Dementia #Neurodegenerative disorders #Neuroinflammation #Neuroscience

This week in drug discovery (21-25 August)  

News round-up for 21-25 August by DDW Digital Content Editor Diana Spencer. The headline news this week reflects the high level of interest and investment in neuroscience drug discovery, particularly neurodegenerative diseases like Alzheimer’s; including positive clinical trial results for new immunotherapy and biotherapeutic candidates, and… Read More

#News

Doctor administering a vaccine to patient
#Alzheimer's #Immune system #Immunology / Virology & Vaccines #Neurodegenerative disorders #Neuroscience

Routine vaccines as effective as antibodies against Alzheimer’s

A new study at UTHealth Houston in the US has found that several routine vaccinations are linked to a significant reduced risk of Alzheimer’s disease (AD). Prior vaccination against tetanus and diphtheria, with or without pertussis (Tdap/Td); herpes zoster (HZ), better known as shingles; and pneumococcus… Read More

#News #Trending News

Neurons in a brain with Alzheimer's disease
#Alzheimer's #epilepsy #Neuroinflammation #Parkinson's #Phase I trial #Ventus Therapeutics

NLRP3 inhibitor for neuroinflammation enters trials

The Phase I clinical trial of VENT-02, an oral, brain-penetrant NLRP3 inhibitor from Ventus Therapeutics, has launched with the dosing of the first patient. Based on the safety margins demonstrated in IND-enabling studies, the Phase I trial is designed to fully explore VENT-02’s pharmacodynamics, safety, and… Read More

#News

CT scans of the brain
#Alzheimer's #Immunotherapy #Neurodegenerative disorders #Phase II trial #Vaxxinity

Alzheimer’s immunotherapy offers safer, cheaper alternative

A new immunotherapy candidate has demonstrated a trend for slowing cognitive decline in mild Alzheimer’s disease (AD), potentially offering a more accessible and cost-effective alternative to other immunotherapies. Vaxxinity published the Phase IIa clinical trial data in The Lancet’s eBioMedicine (Volume 94, 104665, August 2023), stating… Read More

#Editor's Choice #News

Hormones in the brain concept
#ALS #Bloom Science #Clinical trial #Phase I trial #Rare disease

Early trial success for Dravet syndrome and ALS therapeutic

Bloom Science has announced positive topline data from a Phase I clinical trial of BL-001, a potential first-in-class therapeutic the company is developing for Dravet syndrome and amyotrophic lateral sclerosis (ALS). In the trial, BL-001 demonstrated a favourable safety profile and was well… Read More

#News

#Antibody #Antivirals #Immunology / Virology & Vaccines #Neurodegenerative disorders #Neuroscience #Oncology

New DDW Highlights episode out now

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  Diana Spencer has chosen news stories this week which all discuss pre-clinical research studies… Read More

#News

Ozempic Insulin injection pen
#Alzheimer's #Dementia #Nicotine addiction #Novo Nordisk #Type 2 diabetes

Could GLP-1 receptor agonists like Ozempic treat addiction and dementia?

Medications containing semaglutide such as Ozempic, licensed for diabetes, and Wegovy, for weight loss, are being studied to see if they can treat a range of different conditions, including addiction and dementia. Semaglutide manufacturer Novo Nordisk reported earlier this month that the drug reduces the risk… Read More

#News #Trending News